Thursday, August 11, 2022
Proteintech Group today announces that it has established a new subsidiary company, Proteintech Genomics, based out of the thriving life sciences hub of San Diego, California. Proteintech Genomics is building out fully optimized and highly multiplexed proteomic assays to enhance multiomic capabilities across a number of spatial and single cell analysis platforms. The company plans to establish partnerships with leading single cell and spatial analysis companies to develop proteomic assays that can be used together with existing RNA or DNA profiling products.
“Our goal is to unleash the power of multiomics broadly throughout the research community,” said Dr. Kristopher Nazor, CEO, Proteintech Genomics. “This can only be achieved via commercialization of powerful proteomic assays that are highly multiplexed, fully optimized, simple to use, and above all else, reliable.”
“Working as part of the Proteintech Group family of companies provides us with unfettered access to two critical resources,” said Nazor, “An industry-best portfolio of highly validated antibodies targeting the vast majority of the annotated human proteome, and the immense scientific expertise of the teams responsible for building out this industry-best catalog of 15,000+ antibodies.”
“We are excited to announce this new subsidiary within the Proteintech Group family,” said Dr. Jason Li, CEO, Proteintech Group. “The team at Proteintech Genomics has demonstrated leadership in the field of single cell multiomics and there is no limit to what we can achieve together,” adding, “We expect to make a swift and significant impact in the fields of single cell and spatial analysis.”